Allarity Therapeutics, Inc. (ALLR)
- Previous Close
1.6600 - Open
2.0000 - Bid 1.7700 x 100
- Ask 1.8700 x 100
- Day's Range
1.6000 - 2.1000 - 52 Week Range
1.3600 - 666.0000 - Volume
710,000 - Avg. Volume
458,247 - Market Cap (intraday)
2.507M - Beta (5Y Monthly) 0.28
- PE Ratio (TTM)
-- - EPS (TTM)
-10.9800 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.
www.allarity.comRecent News: ALLR
View More
Performance Overview: ALLR
Trailing total returns as of 10/16/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALLR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALLR
View MoreValuation Measures
Market Cap
2.34M
Enterprise Value
-15.56M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.12
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-47.72%
Return on Equity (ttm)
-121.82%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-12.82M
Diluted EPS (ttm)
-10.9800
Balance Sheet and Cash Flow
Total Cash (mrq)
19.23M
Total Debt/Equity (mrq)
6.68%
Levered Free Cash Flow (ttm)
-12.94M
Research Analysis: ALLR
View MoreCompany Insights: ALLR
ALLR does not have Company Insights